Potassium%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520chloride

# Potassium Chloride ## Overview Potassium chloride (KCl) is an essential electrolyte used to prevent or treat hypokalemia. It is available in oral and intravenous formulations. ## Primary Indications * Treatment and prevention of hypokalemia. ## Adult Dosing * **Oral:** Dosing is highly individualized based on serum potassium levels, severity of deficiency, and ongoing potassium losses. * **Prevention:** Typically 20 mEq (10 mmol) per day in divided doses. * **Treatment:** 40-100 mEq (20-50 mmol) per day in divided doses. Maximum typically 20 mEq (10 mmol) per dose to minimize GI irritation. Higher doses may be used in severe cases under close monitoring. * **Intravenous (IV):** * **Mild hypokalemia (serum K 2.5-3.5 mEq/L):** Typically 20-40 mEq (10-20 mmol) in 1 liter of IV fluid over 2-6 hours. Maximum infusion rate is generally 10 mEq (5 mmol) per hour peripherally and up to 20 mEq (10 mmol) per hour centrally, but this can vary based on local protocol and patient's ECG and serum potassium monitoring. * **Severe hypokalemia (serum K < 2.5 mEq/L) or with ECG changes:** May require more rapid infusion, often 20 mEq (10 mmol) per hour, potentially up to 40 mEq (20 mmol) per hour in critical situations via central line, with continuous ECG monitoring and frequent serum potassium checks. Maximum single IV dose generally 40 mEq (20 mmol). Maximum daily IV dose can exceed 200 mEq (100 mmol) in severe cases, but requires intensive monitoring. ## Pediatric Dosing * **Oral:** Dosing is individualized based on age, weight, serum potassium, and degree of deficiency. General guidelines: * **Maintenance:** 1-2 mEq/kg/day (0.5-1 mmol/kg/day), not to exceed 20 mEq (10 mmol) per day. * **Correction:** 2-5 mEq/kg/day (1-2.5 mmol/kg/day) in divided doses, not to exceed 40 mEq (20 mmol) per day. * **Intravenous (IV):** Dosing is individualized. * **General:** 0.3-1 mEq/kg/dose (0.15-0.5 mmol/kg/dose) infused over 1-3 hours. * **Maximum infusion rate:** Typically 0.5-1 mEq/kg/hour (0.25-0.5 mmol/kg/hour), not to exceed 10-20 mEq/hour (5-10 mmol/hour) depending on IV access and monitoring. Higher rates may be used in emergent situations with continuous ECG monitoring. Consult pediatric protocols. ## Dose Adjustments * **Renal Impairment:** Use with extreme caution. Potassium excretion is significantly reduced. Dose reductions are essential. Monitor serum potassium closely. IV potassium is generally contraindicated in severe renal failure. ## Contraindications * Hyperkalemia. * Conditions leading to decreased potassium excretion (e.g., severe renal impairment, untreated Addison's disease, anuria, oliguria). * Certain types of heart block (e.g., heart block with digitalis intoxication). * Known hypersensitivity to potassium chloride. ## Adverse Effects * **Common:** Nausea, vomiting, abdominal pain, diarrhea, flatulence. * **Serious:** * **Hyperkalemia:** Weakness, fatigue, paresthesias, paralysis, cardiac arrhythmias (including bradycardia, asystole, and cardiac arrest), hypotension. Risk is increased with rapid IV infusion, renal impairment, and concomitant use of potassium-sparing agents. * **Gastrointestinal:** Esophageal or gastric ulceration and bleeding, particularly with oral solid dosage forms or if taken without adequate fluid. Bowel perforation. * **Venous irritation/phlebitis:** With IV administration. ## Key Drug Interactions * **Potassium-sparing diuretics (e.g., spironolactone, amiloride, triamterene):** Increased risk of hyperkalemia. * **ACE inhibitors and ARBs:** Increased risk of hyperkalemia. * **NSAIDs:** May decrease potassium excretion and increase risk of hyperkalemia. * **Heparin:** May impair potassium excretion and increase risk of hyperkalemia. * **Digoxin:** Hypokalemia potentiates digoxin toxicity; hyperkalemia reduces efficacy. ## Monitoring * **Serum potassium:** Frequently monitor, especially during IV therapy, dose adjustments, or in patients with renal impairment or ongoing potassium losses. Frequency depends on clinical status and intervention. * **Renal function:** Monitor BUN and creatinine. * **ECG:** Especially with IV administration of rapid rates or when serum potassium is very low or high. * **Signs and symptoms of hypokalemia and hyperkalemia.** ## Clinical Pearls * Oral potassium chloride should be taken with meals or a full glass of water to minimize gastrointestinal irritation. * Concentrated IV potassium chloride solutions are hypertonic and must be diluted before administration to prevent phlebitis and venous irritation. * Never administer concentrated potassium chloride solutions undiluted IV or as an IV bolus. * The goal is to correct hypokalemia while avoiding hyperkalemia. Dosing requires careful titration and monitoring. * Recognize that many IV fluids contain potassium, and total daily intake should be considered. *** **Disclaimer:** This information is intended for clinical use and does not replace the need to consult the official prescribing information and current clinical guidelines. Always verify drug information with the most current resources before prescribing.